Lyrica Cr (Pregabalin) Patent Expiration, LOE Window & CMS Spending

Lyrica Cr (Pregabalin) by Viatris: FDA Orange Book LOE 2027-05-02, 4 AB generics, $339K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN209501 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-05-02
Orange Book Patents (*PED Extensions)6 patents (3 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$339K
2024 Medicare Part D Spend$311K
2024 Medicaid Spend$27K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.